In vitro and in vivo antibacterial activity of the new semisynthetic cephalosporin cefpirome.
Cefpirome (HR 810), a new semisynthetic cephalosporin derivative, was found to have a broad antibacterial spectrum against gram-positive and gram-negative bacteria. Against Staphylococcus aureus, cefpirome was more active than not only cefotaxime and ceftazidime but also cefotiam. Against gram-negative bacteria, especially, Enterobacter cloacae and Citrobacter freundii, it was also more active than the other antibiotics tested, but against Pseudomonas aeruginosa, it was less active than ceftazidime. Cefpirome was stable to hydrolysis by the common plasmid mediated beta-lactamases and was stable to the action of chromosomal cephalosporinases. But it was slightly hydrolyzed by both Rms 213 mediated penicillinase and oxyiminocephalosporinases produced by Proteus vulgaris and Pseudomonas cepacia. When cefpirome was administered subcutaneously to mice experimentally infected with Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae or Pseudomonas aeruginosa, its efficacy well reflected its in vitro potency.
Mitsukude
M
M
Clinical Research Department, Hoechst-Japan Limited, Tokyo.
Inoue
M
M
Mitsuhashi
S
S
D000818:Animals; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D004355:Drug Stability; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000378:metabolism; D000097572:Cefpirome
D002511:Cephalosporins; D001618:beta-Lactamases; D000097572:Cefpirome